Interstitial Lung Disease as an Adverse Drug Reaction in Japan: Exploration of Regulatory Actions as a Basis for High Reporting.
Eiko IwasaYu FujiyoshiYuki KubotaRyota KimuraRebecca E ChandlerHenric TaavolaG Niklas NorénRika WakaoPublished in: Drug safety (2021)
The high rates of interstitial lung disease reporting derived from mainly the anatomical therapeutic chemical classification group L drugs. Interstitial lung disease is the targeted adverse drug reaction in the use-results survey mandated in the re-examination of those drugs. This system provides at least one explanation for the high reporting of interstitial lung disease in Japan.